New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:56 EDTJNJJohnson & Johnson sees FY net interest expense $400M-$500M
Says early Q1 data shows continued softer utilization trends impacted by the severe winter conditions. Says data shows continued slight declines in the rates of surgical and lab procedures in the U.S., similar to what was seen over the past 12 months. Says strong Q4 utilization in orthopedic procedures softened in Q1 due to some seasonality. Says confident overall about the long-term health of the market as economic conditions continue to recover. Says Japanese yen to be a headwind in 2014, although that negative impact to gross margin will increase throughout the year. Sees FY14 net interest expense $400M-$500M, effective tax rate 19%-20%. Says guidance for 2014 anticipates that the R&D tax credit will be renewed by Congress. Says expects continued pricing pressure in 2014 across many markets, particularly in Europe; says impact of this negative pricing pressure to negatively impact pretax operating margin by approximately 50bps. Says "comfortable" with models reflecting an operational sales increase on a constant currency basis of 5%-6% for the year. Says if currency exchange rates for all of 2014 were to remain where they were as of last week, sales growth rate would decrease by nearly half a percent. Says this would result in sales for 2014 on a constant currency basis of approximately $74.9B-$75.7B. Says that if exchange rates for all of 2014 were to remain where they were as of last week, then our reported EPS excluding special items would be positively impacted by approximately 6c per share due solely to exchange rate fluctuations. Comments made on the Q1 earnings conference call.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:50 EDTJNJJ&J may face additional payments of $250M on hip claims, Bloomberg says
Johnson & Johnson may have to pay an additional $250M to settle claims over the failure of its ASR hip implants, says Bloomberg. The current claims were excluded from last year's $2.5B settlement, added Bloomberg. Reference Link
October 29, 2014
11:08 EDTJNJOptions with increasing implied volatility: ACHN CZR ARCP HSY JNJ
Subscribe for More Information
10:17 EDTJNJGilead retreats after Hepatitis C drug sales miss expectations
Shares of drug maker Gilead (GILD) are falling after the company last night announced lower than expected third quarter profits and reported sales of its Hepatitis C treatment, Sovaldi, that came in below expectations. WHAT'S NEW: Gilead reported Q3 earnings per share of $1.84, versus analysts' consensus estimate of $1.92. The company's revenue came in slightly above expectations. Gilead said its Sovaldi drug had generated $2.8B of sales last quarter. On average, analysts had expected sales of the drug to come in at $2.93B. Sales of Sovaldi dropped 20% in Q3 versus Q2. However, the company said on its earnings conference call that the launch of its new Hepatitis C treatment, Harvoni, was off to a strong start. ANALYST REACTION: In a note to investors earlier today, Bernstein analyst Geoffrey Porges wrote that Gilead's Q3 revenue and EPS were reduced by one-time events. Its EPS would have easily beaten expectations if the company did not have to pay one-time taxes related to the Affordable Care Act, Porges stated. The lower than expected Sovaldi sales were caused by a variety of factors, including anticipation of the Harvoni launch, the analyst believes. The challenges facing Sovaldi should not affect Harvoni's performance in Q4 and 2015, added Porges, who remains very upbeat on the company's overall Hepatitis C franchise for the near to medium term. He kept a $130 price target and Outperform rating on the shares. Analysts at UBS also remained positive on Gilead, writing that the company had a good quarter with its HIV franchise that resulted in a top-line beat despite the lower than expected Sovaldi sales. The firm said it remains bullish on the Harvoni launch and sees potential upside to estimates. UBS reiterated its Buy rating and $125 price target on Gilead shares. OTHERS TO WATCH: Other pharmaceutical companies offering and developing Hepatitis C treatments include Johnson & Johnson (JNJ) and Abbvie (ABBV). PRICE ACTION: In early trading, Gilead fell 2% to $111.25.
October 28, 2014
13:09 EDTJNJOptions with increasing implied volatility
Subscribe for More Information
07:21 EDTJNJCBI to hold a conference
Subscribe for More Information
October 27, 2014
07:29 EDTJNJWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
October 24, 2014
08:15 EDTJNJJohnson & Johnson management to meet with JPMorgan
Meetings to be held in Chicago/Kansas City on October 29 hosted by JPMorgan.
06:32 EDTJNJJohnson & Johnson found 'not liable' in all-metal hip implant suit, WSJ reports
Subscribe for More Information
October 23, 2014
05:58 EDTJNJStocks with implied volatility below IV index mean; XLNX JNJ
Subscribe for More Information
October 22, 2014
17:50 EDTJNJBavarian Nordic announces expanded collaboration with Janssen on MVA-BN
Bavarian Nordic A/S announced that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to expand the collaboration announced earlier to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets. Bavarian Nordic and Janssen will collaborate on the evaluation of MVA-BN for three additional infectious disease targets. Janssen is granted the exclusive option to collaborate on one or more of the targets, following scientific evaluation of MVA-BN-based vaccine candidates, which will be developed by Bavarian Nordic.
05:31 EDTJNJJohnson & Johnson announces commitment to speed Ebola vaccine development
Subscribe for More Information
October 20, 2014
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
October 16, 2014
14:47 EDTJNJRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use